Literature DB >> 10706669

Cutting edge: the Ets1 transcription factor is required for the development of NK T cells in mice.

T L Walunas1, B Wang, C R Wang, J M Leiden.   

Abstract

Ets1-deficient mice develop B and T cells but display a severe defect in the development of the NK cell lineage. In this report, we demonstrate that Ets1 is also required for the development of NK1.1+ T (NK T) cells. We observed significantly decreased numbers of NK T cells in the thymus, spleen, and liver of Ets1-deficient mice. These organs also contained markedly decreased levels of the canonical Valpha14-Jalpha281 TCRalpha transcript seen in NK T cells. Unlike wild-type NK T cells, Ets1-deficient thymocytes failed to produce detectable levels of IL-4 following anti-CD3 stimulation. The absence of NK T cells in the Ets1-deficient mice was not associated with defective expression of CD1, an MHC class I molecule required for NK T cell development. We conclude that Ets1 defines a novel transcriptional regulatory pathway that is required for the development of both the NK and NK T cell lineages.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10706669     DOI: 10.4049/jimmunol.164.6.2857

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

Review 1.  Innate self recognition by an invariant, rearranged T-cell receptor and its immune consequences.

Authors:  Aleksandar K Stanic; Jang-June Park; Sebastian Joyce
Journal:  Immunology       Date:  2003-06       Impact factor: 7.397

Review 2.  The ins and outs of type I iNKT cell development.

Authors:  Susannah C Shissler; Tonya J Webb
Journal:  Mol Immunol       Date:  2018-11-28       Impact factor: 4.407

3.  Commitment toward the natural T (iNKT) cell lineage occurs at the CD4+8+ stage of thymic ontogeny.

Authors:  Jelena S Bezbradica; Timothy Hill; Aleksandar K Stanic; Luc Van Kaer; Sebastian Joyce
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-25       Impact factor: 11.205

Review 4.  Raising the NKT cell family.

Authors:  Dale I Godfrey; Sanda Stankovic; Alan G Baxter
Journal:  Nat Immunol       Date:  2010-02-07       Impact factor: 25.606

5.  Transcription factor Bcl11b controls selection of invariant natural killer T-cells by regulating glycolipid presentation in double-positive thymocytes.

Authors:  Diana I Albu; Jeffrey VanValkenburgh; Nicole Morin; Danielle Califano; Nancy A Jenkins; Neal G Copeland; Pentao Liu; Dorina Avram
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-28       Impact factor: 11.205

Review 6.  Regulation of endothelial cell development by ETS transcription factors.

Authors:  Stryder M Meadows; Candace T Myers; Paul A Krieg
Journal:  Semin Cell Dev Biol       Date:  2011-09-18       Impact factor: 7.727

7.  Invariant NKT cell development requires a full complement of functional CD3 zeta immunoreceptor tyrosine-based activation motifs.

Authors:  Amy M Becker; Jon S Blevins; Farol L Tomson; Jennifer L Eitson; Jennifer J Medeiros; Felix Yarovinsky; Michael V Norgard; Nicolai S C van Oers
Journal:  J Immunol       Date:  2010-05-14       Impact factor: 5.422

8.  Multiple layers of transcriptional regulation by PLZF in NKT-cell development.

Authors:  Ai-Ping Mao; Michael G Constantinides; Rebecca Mathew; Zhixiang Zuo; Xiaoting Chen; Matthew T Weirauch; Albert Bendelac
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-20       Impact factor: 11.205

9.  Caspase-1 is a direct target gene of ETS1 and plays a role in ETS1-induced apoptosis.

Authors:  Huiping Pei; Chunyang Li; Yair Adereth; Tien Hsu; Dennis K Watson; Runzhao Li
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

10.  Mouse Hobit is a homolog of the transcriptional repressor Blimp-1 that regulates NKT cell effector differentiation.

Authors:  Klaas P J M van Gisbergen; Natasja A M Kragten; Kirsten M L Hertoghs; Felix M Wensveen; Stipan Jonjic; Jörg Hamann; Martijn A Nolte; Rene A W van Lier
Journal:  Nat Immunol       Date:  2012-08-12       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.